Keywords: serono, overturns, biogen, orphan, exclusivity, interferon, beta-1a

Serono overturns Biogen's US orphan exclusivity for interferon beta-1a

Article | 18 March 2002

Print This

Serono of Switzerland can launch its Rebif (interferon beta-1a) productfor the treatment of multiple sclerosis in the USA, having ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in